Home >> About

News & Events

In the early 1980s, the quest for a better anti-depressant was the focus of intense research aimed at designing novel serotonin re-uptake inhibitors. While most scientists focused solely on serotonin as a target however, the medicinal chemists’ team at Wyeth Pharmaceuticals, led by Magid Abou-Gharbia, was determined to go after two neurotransmitters, serotonin and norepinephrine.

Pages

Temple University
Moulder Center for Drug Discovery Research

Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140